The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
Abstract
BACKGROUND & AIMS: We compared the effects of weight loss induced with the glucagon-like peptide-1 agonist liraglutide, with that of lifestyle modification, followed by weight maintenance after discontinuing intervention, in obese adults with non-alcoholic fatty liver disease (NAFLD). METHODS: , 90% male) adults with NAFLD defined as liver fat fraction (LFF) > 5% on magnetic resonance imaging without other causes of hepatic steatosis were randomized to a supervised programme of energy restriction plus moderate-intensity exercise to induce ≥ 5% weight loss (DE group, n = 15), or liraglutide 3 mg daily (LI group, n = 15) for 26 weeks, followed by 26 weeks with only advice to prevent weight regain. RESULTS: Diet and exercise and LI groups had significant (P < 0.01) and similar reductions in weight (-3.5 ± 3.3 vs -3.0 ± 2.2 kg), LFF (-8.1 ± 13.2 vs -7.0 ± 7.1%), serum alanine aminotransferase (-39 ± 35 vs -26 ± 33 U/L) and caspase-cleaved cytokeratin-18 (cCK-18) (-206 ± 252 vs -130 ± 158 U/L) at 26 weeks. At 52 weeks, the LI group significantly (P < 0.05) regained weight (1.8 ± 2.1 kg), LFF (4.0 ± 5.3%) and cCK-18 (72 ± 126 U/L), whereas these were unchanged in the DE group. CONCLUSIONS: Liraglutide was effective for decreasing weight, hepatic steatosis and hepatocellular apoptosis in obese adults with NAFLD, but benefits were not sustained after discontinuation, in contrast with lifestyle modification. Continuing the exercise learned in the structured programme contributed to the maintenance of liver fat reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immediately following treatment, and similar to our observations, the reductions in weight and liver fat content were similar”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [28]
In the citing paper
“Two published studies have used higher doses of liraglutide (3 mg) with a 26-week intervention period.”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [28]
In the citing paper
“there was increased weight regain in the liraglutide-treated group compared with the lifestyle intervention arm.28,29”
From Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD (2025) · cites this paper as [28]
Citations
Cites
2011 Compendium of Physical Activities: A Second Update of Codes and MET Values
AINSWORTH, B. E., HASKELL, W. L., HERRMANN, S. D., MECKES, N., BASSETT, D. R., TUDOR-LOCKE, C., GREER, J. L., VEZINA, J., WHITT-GLOVER, M. C., & LEON, A. S. (2011) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31821ece12 · Cited by 6,317
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
DONNELLY, J. E., BLAIR, S. N., JAKICIC, J. M., MANORE, M. M., RANKIN, J. W., & SMITH, B. K. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181949333 · Cited by 2,658
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
Szczepaniak, L. S., Nurenberg, P., Leonard, D. S., Browning, J. D., Reingold, J. S., Grundy, S. M., Hobbs, H. H., & Dobbins, R. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,573
Franz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.017 · Cited by 1,559
Regulation of hepatic glucose metabolism in health and disease
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.80 · Cited by 1,159
Cited by
Sorted by citations
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 387
Nahra, R., Wang, T., Gadde, K. M., Oscarsson, J., Stumvoll, M., Jermutus, L., Hirshberg, B., & Ambery, P. (2021) · Diabetes Care · doi:10.2337/dc20-2151 · Cited by 323
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives
Hu, H., Lin, A., Kong, M., Yao, X., Yin, M., Xia, H., Ma, J., & Liu, H. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01649-8 · Cited by 211
Non-alcoholic fatty liver disease: A patient guideline
Francque, S. M., Marchesini, G., Kautz, A., Walmsley, M., Dorner, R., Lazarus, J. V., Zelber-Sagi, S., Hallsworth, K., Busetto, L., Frühbeck, G., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100322 · Cited by 264
Management of non-alcoholic fatty liver disease
Petroni, M. L., Brodosi, L., Bugianesi, E., & Marchesini, G. (2021) · BMJ · doi:10.1136/bmj.m4747 · Cited by 193
Kanwal, F., Kramer, J. R., Li, L., Yang, Y., Cao, Y., Yu, X., Samuel, R. E., Ali, B., Desiderio, R., Cholankeril, G. T., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4661 · Cited by 170
West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., et al. (2026) · BMJ · doi:10.1136/bmj-2025-085304 · Cited by 174
Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
Liu, Y., Ruan, B., Jiang, H., Le, S., Liu, Y., Ao, X., Huang, Y., Shi, X., Xue, R., Fu, X., et al. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.04.017 · Cited by 121
Ranjbar, G., Mikhailidis, D. P., & Sahebkar, A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154001 · Cited by 109
Berg, S., Stickle, H., Rose, S. J., & Nemec, E. C. (2025) · Obesity Reviews · doi:10.1111/obr.13929 · Cited by 111
GLP-1a: Going beyond Traditional Use
Laurindo, L. F., Barbalho, S. M., Guiguer, E. L., da Silva Soares de Souza, M., de Souza, G. A., Fidalgo, T. M., Araújo, A. C., de Souza Gonzaga, H. F., de Bortoli Teixeira, D., de Oliveira Silva Ullmann, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020739 · Cited by 102
Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis
Tang, Y., Huang, J., Zhang, W. Y., Qin, S., Yang, Y. X., Ren, H., Yang, Q.-B., & Hu, H. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819878046 · Cited by 85
Flessa, C., Kyrou, I., Ansari, N. N., Kaltsas, G., Papavassiliou, A. G., Kassi, E. N., & Randeva, H. S. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00431-3 · Cited by 81
Galiero, R., Caturano, A., Vetrano, E., Cesaro, A., Rinaldi, L., Salvatore, T., Marfella, R., Sardu, C., Moscarella, E., Gragnano, F., et al. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203082 · Cited by 86
Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 79
Dougherty, J. A., Guirguis, E. H., & Thornby, K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020935105 · Cited by 77
Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 76
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kim, K., & Lee, B. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0137 · Cited by 69
Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease
Kothari, S., Dhami-Shah, H., & Shah, S. R. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.06.003 · Cited by 65
Liao, C., Liang, X., Zhang, X., & Li, Y. (2023) · PLOS ONE · doi:10.1371/journal.pone.0289616 · Cited by 63
Bischoff, S. C., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Eshraghian, A., Kani, H. T., Khannoussi, W., Lacaze, L., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.07.003 · Cited by 70
Bischoff, S. C., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Eshraghian, A., Kani, H. T., Khannoussi, W., Lacaze, L., et al. (2022) · United European Gastroenterology Journal · doi:10.1002/ueg2.12280 · Cited by 62
Quarenghi, M., Capelli, S., Galligani, G., Giana, A., Preatoni, G., & Quarenghi, R. T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113791 · Cited by 61
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Reis‐Barbosa, P. H., Marcondes‐de‐Castro, I. A., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101922 · Cited by 52
Lee, H. A., & Kim, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119324 · Cited by 52
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 52
Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud’homme, G. J., & WANG, Q. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf336 · Cited by 52
Bischoff, S. C., Ockenga, J., Eshraghian, A., Barazzoni, R., Busetto, L., Campmans-Kuijpers, M. J. E., Cardinale, V., Chermesh, I., Kani, H. T., Khannoussi, W., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.03.021 · Cited by 47
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44
Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease
Nawrot, M., Peschard, S., Lestavel, S., & Staels, B. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154844 · Cited by 49
Abdelmalek, M. F., Harrison, S. A., & Sanyal, A. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15524 · Cited by 45
Kongmalai, T., Srinonprasert, V., Anothaisintawee, T., Kongmalai, P., McKay, G. J., Attia, J., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1182037 · Cited by 43
Feng, X., Zhang, R., Yang, Z., Zhang, K., & Xing, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00019 · Cited by 45
Barritt, A. S., Marshman, E., & Noureddin, M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16794 · Cited by 43
Incretin-based investigational therapies for the treatment of MASLD/MASH
Brouwers, B., Rao, G., Tang, Y., Rodríguez, Á., Glass, L. C., & Hartman, M. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111675 · Cited by 40
Gu, Y., Sun, L., Zhang, W., Kong, T., Zhou, R., He, Y., Deng, C., Yang, L., Kong, J., Chen, Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1102792 · Cited by 46
Lupianez‐Merly, C., Dilmaghani, S., Vosoughi, K., & Camilleri, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17856 · Cited by 41
Perakakis, N., Stefanakis, K., Feigh, M., Veidal, S. S., & Mantzoros, C. S. (2021) · Liver International · doi:10.1111/liv.14888 · Cited by 41
Moon, S., Lee, J., Chung, H. S., Kim, Y. J., Yu, J. M., Yu, S. H., & Oh, C.-M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.934 · Cited by 38
Mantovani, A., Morandin, R., Fiorio, V., Lando, M. G., Stefan, N., Tilg, H., Byrne, C. D., & Targher, G. (2025) · Liver International · doi:10.1111/liv.70256 · Cited by 50
Dai, Y., He, H., Li, S., Yang, L., Wang, X., Liu, Z., & An, Z. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.622589 · Cited by 38
Kuo, C., Chuang, M., Li, C., Tsai, Y., Huang, P., Kuo, H., & Lai, C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18502 · Cited by 40
Wu, H., Yang, W., Guo, T., Cai, X., & Ji, L. (2025) · BMC Medicine · doi:10.1186/s12916-025-04200-0 · Cited by 36
Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
Fu, Y., Zhou, Y., Shen, L., Li, X., Zhang, H., Cui, Y., Zhang, K., Li, W., Chen, W., Zhao, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.973366 · Cited by 36
Glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
Sofogianni, A., Filippidis, A., Chrysavgis, L., Tziomalos, K., & Cholongitas, E. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i8.493 · Cited by 33
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Zachou, M., Flevari, P., Ansari, N. N., Varytimiadis, C., Kalaitzakis, E., Kassi, E. N., & Ανδρουτσάκος, Θ. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03586-1 · Cited by 38
Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients
Brodosi, L., Petta, S., Petroni, M. L., Marchesini, G., & Morelli, M. C. (2021) · Transplantation · doi:10.1097/tp.0000000000003867 · Cited by 34
Moolla, A., Poolman, T., Othonos, N., Dong, J., Smith, K., Cornfield, T., White, S., Ray, D. W., Mouchti, S., Mózes, F. E., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101363 · Cited by 33
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 31
Hu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 34
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 36
Ayesh, H., Beran, A., Suhail, S., Ayesh, S. K., & Niswender, K. D. (2024) · Biomedicines · doi:10.3390/biomedicines12102328 · Cited by 23
Chrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 26
Xie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 22
Kalogirou, M., Patoulias, D., Haidich, A., Akriviadis, E. A., & Sinakos, E. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.10.012 · Cited by 17
Chang, Q., Zhang, Y., Zhang, T., Liu, Z., Cao, L., Zhang, Q., Liu, L., Sun, S., Wang, X., Zhou, M., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0133 · Cited by 18
Kim, M. N., Han, K., Yoo, J., Ha, Y., Chon, Y. E., Lee, J. H., Simon, T. G., Chan, A. T., & Hwang, S. G. (2021) · Scientific Reports · doi:10.1038/s41598-021-88733-3 · Cited by 17
Byrne, C. D. (2022) · Diabetic Medicine · doi:10.1111/dme.14912 · Cited by 17
Tamilwanan, S., Aziz, Z., Rong, L. Y., Bitar, A. N., Zarzour, R. A., & Alshehade, S. A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04358-0 · Cited by 21
Njei, B. M., Al‐Ajlouni, Y. A., Lemos, S. Y., Ugwendum, D. F., Ameyaw, P. A., Njei, L., & Boateng, S. (2024) · Cureus · doi:10.7759/cureus.71366 · Cited by 19
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Knezović, E., Hefer, M., Blažanović, S., Petrović, A., Tomičić, V., Srb, N., Kirner, D., Smolić, R., & Smolić, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030154 · Cited by 16
Xu, R., Liu, B., & Zhou, X. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.017 · Cited by 16
Shiomi, M., Tanaka, Y., Takada, T., & Otori, K. (2020) · JGH Open · doi:10.1002/jgh3.12384 · Cited by 13
Ala, M., & Eftekhar, S. P. (2023) · Obesity Reviews · doi:10.1111/obr.13563 · Cited by 15
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 15
Huang, X., Wu, M., Huang, B., & Zhang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1509947 · Cited by 12
Yu, X., Wang, Y., Lai, J., Song, T., & Duan, J. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-022-02988-x · Cited by 12
Comparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis
Jin, D., Cui, Z., Jin, S., Zhou, T., Guo, B., Gao, P., & Li, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1096064 · Cited by 12
Liu, L., Xia, Y., Wang, B., & Zhang, Y. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70084 · Cited by 13
Wang, H., Ma, Q., Chen, Y., Luo, L., Ye, J., & Zhong, B. (2024) · Obesity Reviews · doi:10.1111/obr.13727 · Cited by 15
Potter, K. J., Phinney, J., Kulai, T. B., & Munro, V. (2025) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwae057 · Cited by 13
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 15
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 18
Paredes-Marin, A., He, Y., & Zhang, X. (2025) · Nutrients · doi:10.3390/nu17213491 · Cited by 10
Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?
Tsankof, A., Neokosmidis, G., Koureta, E., Veneti, S., Cholongitas, Ε., & Τζιόμαλος, Κ. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.984041 · Cited by 11
Zou, C., Sun, Y., & Liang, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.102053 · Cited by 11
García‐Compeán, D., Kumar, R., del Cueto-Aguilera, Á. N., Maldonado-Garza, H. J., & Villarreal‐Pérez, J. Z. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100751 · Cited by 10
Dietary and pharmacological energy restriction and exercise for healthspan extension
Cagigas, M. L., Ciutiis, I. D., Masedunskas, A., & Fontana, L. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.04.001 · Cited by 12
Tornea, D. A., Goldiș, C., Isaic, A., Motofelea, A. C., Sima, A. C., Ciocârlie, T., Crintea, A., Diaconescu, R. G., Motofelea, N., & Goldiș, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010086 · Cited by 13
Causes and consequences of discontinuation of GLP1RAs or tirzepatide
Ceriello, A., Prattichizzo, F., Abdullah, A. R. M. S., Grotta, R. L., Berra, C., McGowan, B. M., Jenkins, A., Cohen, N. D., Nauck, M. A., & Russo, G. T. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01258-5 · Cited by 21
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms
Møller, S., Kimer, N., Kronborg, T. M., Grandt, J., Hove, J. D., Barloese, M. C. J., & Gluud, L. L. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1725022 · Cited by 10
New Drugs on the Block—Emerging Treatments for Nonalcoholic Steatohepatitis
Stojsavljević, S., Duvnjak, M., Virović-Jukić, L., Hrabar, D., & Duvnjak, L. S. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00057 · Cited by 9
Zhao, D., Liu, H., & Dong, P. (2019) · Clinical and Experimental Hypertension · doi:10.1080/10641963.2019.1676771 · Cited by 9
Kolli, R. T., Aoutla, S., Jyothi, N., Mohamed Kalifa, M. R. H., Raju, A., & Cheenikkal Muralidharan, K. (2025) · Cureus · doi:10.7759/cureus.94926 · Cited by 7
Zhou, L., Wei, A., Pan, C., Zhang, J., Hu, P., Li, X., Zhao, X., Hu, Y., He, B., Liu, Y., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09950-4 · Cited by 7
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk
Nysather, J. A., Kaya, E., Manka, P. P., Gudsoorkar, P. S., & Syn, W. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.04.001 · Cited by 7
The role of glucagon-like peptide-1 receptor agonists in nonalcoholic fatty liver disease
Tsiampali, C., Papaioannidou, P., Goulas, A., & Pοlyzos, S. A. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2274536 · Cited by 9
Akuta, N., Kogiso, T., Ikejima, K., Otsuka, M., Kawaguchi, T., Kawanaka, M., Takahashi, H., Tamaki, N., Nakagawa, H., 疋田隼人, et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02408-2 · Cited by 9
Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Katsarou, A., Tsioulos, G., Kassi, E. N., & Chatzigeorgiou, A. (2024) · HORMONES · doi:10.1007/s42000-024-00588-1 · Cited by 8
Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease
Muzurović, E. M., Haluzík, M., Horváth, L., Vlacho, B., & Mauricio, D. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128378484250619080753 · Cited by 5
Treating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach
Li, X., Rao, Z., Hu, W., Lu, W., & Luo, Y. (2024) · Obesity Reviews · doi:10.1111/obr.13861 · Cited by 6
Bai, J., Zhang, L., He, L., & Zhou, Y. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1613640 · Cited by 6
Liraglutide for adults living with obesity
Meza, N., Bracchiglione, J., Liquitay, C. M. E., Eva Madrid, A., Varela, L. B., Guo, Y., Urrútia, G., er, S. F. S., Tiller, S., Shokraee, K., et al. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016017 · Cited by 5
The Evolving Role of GLP-1 Receptor Agonists in MASLD: Current Evidence and Future Directions
Zasadzińska, M., Borowski, G., Bakuła, P. R., & Jałocha, K. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_18_25 · Cited by 3
Metadata
- Authors
- Khoo, J., Hsiang, J. C., Taneja, R., Koo, S., Soon, G., Kam, C. J., Law, N., & Ang, T.
- Affiliations
- Changi General Hospital (SG)
- Corresponding author
- Khoo, Joan
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2019-02-24
- Volume
- 39
- Issue
- 5
- Pages
- 941-949
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W2913917435
- Cited by
- 136
- References
- 42
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 21 · 2023: 18 · 2022: 18 · 2021: 16 · 2020: 7 · 2019: 7
- FWCI
- 9.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Liver International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Medical Research Council (NMRC/CG/002/2013)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, non-alcoholic fatty liver disease, weight loss, lifestyle modification, caloric restriction, physical activity, GLP-1 receptor agonists, hepatic steatosis, liver fat fraction, hepatocyte apoptosis, caspase-cleaved cytokeratin 18, weight regain, obesity
- MeSH terms
- Liraglutide, Healthy Lifestyle, Adult, Female, Humans, Hypoglycemic Agents, Liver, Male, Middle Aged, Obesity, Prospective Studies, Singapore, Weight Loss, Exercise, Body Mass Index, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
